BIOplus 2018 : Game-changing insights and the latest research on immune checkpoint inhibitors for cancer therapy from GlobalData’s Fern Barkalow

BIOplus 2018 which takes place in Seoul next month (September 6th – 7th), will reveal the latest global intelligence in biotech and healthcare developments, focusing on game-changing insights to help bio companies grow their business.

Fern Barkalow, PhD, Healthcare Director of Oncology and Hematology at GlobalData will join a presentation panel on the subject of ‘antibody and immune checkpoint inhibitors’, to share the company’s latest research findings and key opinion leader insights in the development of immune checkpoint inhibitors for cancer therapy.

Dr Barkalow commented, “Given the increasingly crowded landscape for marketed PD-1/L1 inhibitors across many tumor types, research into novel checkpoint targets is moving forward, with quite a few drugs now in late-phase development in Asia, Europe and the US.

‘‘While we expect to see the first approval for a new PD-1 drug in an indication that does not currently have any marketed checkpoint inhibitors in Q4, we also anticipate some promising trial readouts for drugs with novel checkpoint targets over the next few years.”

Dr Barkalow’s presentation will cover several core subject areas, namely:

the incorporation of checkpoint inhibitors into the treatment paradigm of various cancers

the state of predictive biomarkers

further strategies including combination therapies and novel targets

an overview of the current landscape of marketed and pipeline checkpoint inhibitors therapies.

The presentation content will be drawn from a number of company sources including GlobalData’s post-ASCO expert presentation and the latest pharma reports on the subject area, including: ‘Challenges in Immuno-oncology (I-O): Future Use, Trial Design and Combination Strategies’ and ‘PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities’.

BIOplus 2018

BIOplus 2018 is hosted by the Korea Biotechnology Industry Organization (KoreaBIO) and supported by MOTIE (Ministry of Trade, Industry and Energy).

The programme will include the latest trends and developments in AI and new drugs, cell and gene therapy, the bio-based chemical industry, microbiome, gene editing, the brain, precision medicine, antibody and immune checkpoint inhibitors, healthcare in the Korean peninsula, bio-medical 3D printing, digital healthcare and the Korean pharmacal research and development.


For more information

To gain access to our latest press releases: GlobalData Media Centre Analysts available for comment. Please contact the GlobalData Press Office: Email:

EMEA & Americas: +44 (0)207 832 4399

BIOplus 2018 contact information

Sung Hyun Kim,

Manager of BIOplus Team.

Korea Bio.

Tel : 031.628.0036

E-mail :

To gain access to our latest press releases and expert analysis on developments in your industry, please connect with us on: | LinkedIn | Twitter

About GlobalData

4,000 of the world’s largest companies, including over 70% of FTSE 100 and 60% of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData’s unique data, expert analysis and innovative solutions, all in one platform. GlobalData’s mission is to help our clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, financial, technology and professional services sectors. PR2437

Back to news